Imatinib is a tyrosine kinase inhibitor primarily used to treat certain types of cancer. It specifically targets the BCR-ABL protein, which is produced by the Philadelphia chromosome abnormality found in various cancers. Imatinib is commonly known by its brand name, Gleevec.
